ABSTRACT
Objective The aim of this study was to evaluate the clinical efficacy and hematologic toxicity of docetaxel in the treatment of metastatic breast cancer patients in different age groups. Methods The clinical data of three groups of single-agent do-cetaxel in the treatment of metastatic breast cancer patients were retrospectively analyzed. The clinical efficacy of docetaxel was ana-lyzed statistically. Results The objective response rate(ORR) and clinical beneficial rate( CBR) in the group of age < =45 year group were 30. 6% and 38. 7% ,and the ORR and CBR in the 46~59 age were 27. 5% and 35. 7% ,while ORR and CBR in the≥60 age group were 20. 0% and 27. 5% . The median progress free survival( PFS) in three groups was 6. 0(2. 9 ~9. 1) months,5. 0 (2. 9~7. 1)months and 4. 0(3. 3~4. 7) months,respectively. There was no statistical difference in three different age groups(P=0. 477,0. 492 and 0. 460,respectively). Cox regression analysis showed that the docetaxel rescue treatment of PFS had not associated with clinical stage,pathological type,ipsilateral axillary lymph node metastasis,disease free survival,unit dose of body surface area dose,number of rescue treatment lines,number of recurrence and metastasis,etc. in three different age groups of patients with meta-static breast cancer. Hematological toxicity was mainly manifested by a decrease in white blood cells and neutrophils,and docetaxel has less effect on hemoglobin and platelets. Conclusion The clinical efficacy and hematologic toxicity of docetaxel have a certain de-gree of correlation with ages. With the increase of age,the clinical curative effect is reduced and the blood toxicity is aggravated.
ABSTRACT
ObjectiveBoth BI-RADS 3 and 4A breast lumps have certain effects on the clinician's decision of proper treatment. The purpose of this study was to compare the ultrasonic BI-RADS classification and pathological results of breast lumps in patients of different ages, and explore the significance of age in ultrasound interpretation of BI-RADS 3 and 4A breast lumps.MethodsWe selected 728 patients with breast lumps treated in our hospital from Jun. 2014 to Dec. 2017 as research objects. According to different ages, the patients were divided into juvenile group (7-17 years old) , young group (18-40 years old), middle-aged group (41-65 years old) and aged group (> 65 years). Comparison was made between ultrasound results and pathological results and among the incidences of breast malignant masses of BI-RADS 3 and 4A grade of different ages to analyze possible factors that might affect the benign and malignant breast lumps of BI-RADS 3 and 4A.ResultsA total number of 728 patients was included in this study. Compared with pathological results, the rate of malignant breast tumors in BI-RADS 3 and 4A gradually increased with age. As to BI-RADS 3 breast lumps, the malignant rate of BI-RADS 3(6.54%) in aged group was higher than those of juvenile group(0.00%), young group (0%), middle-aged group (0.95%) and the differences were of statistical significance (P<0.05). As to BI-RADS 4A breast lumps, the malignant rate of juvenile group(0%) was lower than those of young group (2.06%), middle-aged group(6.54%) and aged group(25.39%), and the malignant rate in the elderly group was higher than those of the other groups(P<0.05). Logistic results showed age (OR=1.21,95%CI:1.07~1.36) and weight (OR=3.87,95%CI:1.24~12.81) were risk factors for breast cancer.ConclusionAge plays an important role in the ultrasound interpretation of BI-RADS 3 and 4A breast lumps. For young people, clinical assessment of BI-RADS 4A breast lumps by ultrasound can be properly degraded. While for elderly people, clinical assessment of BI-RADS 3 and 4Abreast lumps can be properly upgraded.